Clinical observation of Bifidobacterium,lactobacillus and Enterococcus capsules combined with triple therapy in eradicating helicobacter pylori infection
Objective:To investigate Live combined Bifidobacterium,lactobacil us and Enterococcus capsules combinded with triple therapy of Helicobacter pylori infection associated peptic ulcer clinical efficacy. Methods:From Jan 2012 to Dec 2012, 68 cases of patients with peptic ulcer data were randomly divided into observation group and control group, 32 cases in the control group were treated with triple therapy;36 cases in the observation group .After 10days triple therapy. observation group took Live combined Bifidobacterium,lactobacil us and Enterococcus capsules ,2#, tid×14d. Four weeks after the end of treatment, ulcer patients endoscopy to observe H.pylori infection and ulcer healing degree;the 13C-urea breath test, H.pylori eradication rate was observed. Also observed adverse reactions in patients. Results:The patients H.pylori clearance rate ,the total effective rate is 86.2%and there is a low incidence of adverse reactions in the observation group, There is a significantly difference between tow groups (P<0.05). Conclusion:The combination of Live combined Bifidobacterium,lactobacil us and Enterococcus capsules with triple therapy treated Helicobacter pylori infection, the clinical results were satisfactory, worthy of clinical application.
Live combined Bifidobacterium,lactobacillus and Enterococcus capsulesTriple therapyHelicobacter pyloriPeptic ulcer